Grifols SA
GRFS
Company Profile
Business description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Contact
Avinguda de la Generalitat, 152
Parc de Negocis Can Sant Joan
Sant Cugat del Valles
Barcelona08174
ESPT: +34 935712200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
23,554
Stocks News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,052.70 | 80.40 | -0.99% |
| CAC 40 | 7,858.83 | 17.53 | -0.22% |
| DAX 40 | 22,390.84 | 149.14 | -0.66% |
| Dow JONES (US) | 42,225.32 | 235.36 | 0.56% |
| FTSE 100 | 8,608.48 | 26.32 | -0.30% |
| HKSE | 22,843.50 | 359.03 | -1.55% |
| NASDAQ | 17,601.05 | 151.16 | 0.87% |
| Nikkei 225 | 34,688.87 | 1,037.00 | -2.90% |
| NZX 50 Index | 12,338.57 | 18.38 | 0.15% |
| S&P 500 | 5,670.97 | 37.90 | 0.67% |
| S&P/ASX 200 | 7,859.70 | 74.80 | -0.94% |
| SSE Composite Index | 3,342.94 | 7.18 | -0.21% |